Lina B. Karam, MD
Department or Service
- Texas Medical Center
Director of Capsule Endoscopy
Texas Children's Hospital
Assistant Professor of Pediatrics, Baylor College of Medicine
|University of Michigan Medical School||residency||Pediatrics||2003|
|University of Michigan||fellowship||Pediatric Gastroenterology||2001|
|Medical University of South Carolina||fellowship||Pediatric Gastroenterology||2000|
|American University of Beirut||residency||Pediatrics||1998|
|American University of Beirut||residency||Anesthesiology||1995|
|Saint Joseph University||medical school||Doctor of Medicine||1994|
Lina B. Karam M.D is a Pediatric Gastroenterologist with clinical expertise in treatment of patients with a variety of gastrointestinal disorders and a special interest in patients with inflammatory bowel disease. She is the medical director of the capsule endoscopy program which is a state of the art technology that allows us to examine the area of the bowel that cannot be reached by regular upper or lower endoscopy. Dr Karam has special interest in the area Inflammatory Bowel Disease especially Very Early Onset Inflammatory Bowel Disease and the role of genetics. She is involved in multicenter national study with Crohn’s Colitis Foundation in patients with very early onset inflammatory bowel disease.
Capsule Endoscopy role in the study and treatment of small bowel disorders
Capsule Endoscopy Curriculum development
Inflammatory bowel disease in general and more specifically for Early and Very Early Onset IBD
|American Academy of Pediatrics||Member (6/2001-present)|
|American Gastroenterological Association||Member (06/2007 – present)|
|Crohn’s Colitis Foundation of America||Member (06/2007-present)|
|North American Society for Pediatric Gastroenterology and Nutrition||Member (06/1999 – present)|
Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, Lyons JJ, Engelhardt KR, Zhang Y, Topcagic N, Roberson ED, Matthews H, Verbsky JW, Dasu T, Vargas-Hernandez A, Varghese N, McClain KL, Karam LB and Cooper MA. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015 Jan 22; 125(4):591-9.
Cruz AT, Karam LB, Orth RC, Starke JR. Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab. Pediatric Infectious Diseases Journal 2014 Jul; 33(7):779-81.
Karam LB, Disco D, Jackson SM, Lewin D, McKie V, Baker RD, Baker SS, Laver JH, Nietert PJ, Abboud MR. Pediatric Blood & Cancer 2008 Jan; 50(1):62-5